ResMed Inc.

$RMD - NYSE - Healthcare Equipment/Supplies
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 0
WATCHLISTS

COMMUNIQUÉ DETAILS

posts/post

Press Release $RMD ResMed Inc.

0 COMMENTs 12 Dec
Up 0 0 Down
NovaSom Adds VP of Sales to Accelerate Home Sleep Test Momentum

Sleep Industry Leader Stefan Elterich Was Formerly VP Sales & Channel Management – Americas for ResMed

GLEN BURNIE, Md.--(BUSINESS WIRE)-- NovaSom, Inc., the leader in home sleep testing and cost-saving solutions for Obstructive Sleep Apnea (OSA) management, has hired a new senior executive, Stefan Elterich.

Leading all sales functions, Elterich will join the company’s Executive Committee, shaping its strategic decisions. Elterich was previously with ResMed (NYSE: RMD), a global leader in medical equipment for treating, diagnosing and managing sleep-related respiratory disorders, which he joined in 2002, rising to Vice President Sales & Channel Management - Americas, managing over $700 million in revenue and achieving double-digit revenue growth. There, Stefan had responsibility for sales, channel management, health economics and sales operations. Prior to ResMed, Stefan held a variety of sales management and strategic sales roles at Abbott Laboratories’ Ross Products Division, following success with MCI, IBM and the United States Air Force National Guard.

Richard Hassett, MD, CEO of NovaSom, said, “Stefan is a great sales leader with deep industry knowledge and a proven record of managing rapid growth. He is a high energy team-builder, joining a strong in-place sales team at a time when rapid expansion of our industry is occurring. This is a perfect opportunity for NovaSom to leverage its industry leading position and accelerate growth.”

“It’s an exciting time to be joining,” said Elterich, VP of Sales. “NovaSom’s leadership in a rapidly growing space is compelling. At a time when every stakeholder in healthcare is looking for improved outcomes at reduced cost, NovaSom is accomplishing that, opening up opportunities to address a massively under-diagnosed 40 million person epidemic. The company has invested in the technology assets to enable scale. The current sales team is quite attuned to the sleep marketplace in the United States and we are poised for rapid growth.”

“I am looking forward to working side by side with Stefan,” said Bill McIvor, VP, Business Development. An accomplished veteran of managed care and healthcare information technology, McIvor noted, “NovaSom has built integrated solutions and industry leading relationships with employers, providers and payers eager to address the undiagnosed OSA epidemic. Stefan will undoubtedly help us accelerate our growth curve.”

NovaSom offers turnkey solutions for the diagnosis of uncomplicated adult OSA at home. Built around its proprietary, cloud-based operating system, MediTrack® and its Verizon-enabled AccuSom® device, its suite of solutions include AccuSom at Home™, for Primary Care Physicians seeking a quality home sleep test interpreted by a board certified sleep specialist; AccuSom Deliver™, customized for Sleep Centers offering at-home testing; and AccuSom Safe Recovery™, enabling rapid identification of OSA prior to elective surgery.

About OSA

Obstructive Sleep Apnea (OSA) affects 40 million Americans, of which 18 million have moderate to severe disease. Of these, a startling 85% of sufferers are undiagnosed and therefore untreated, generating significant medical expense for patients and the healthcare system. Nearly half of all OSA patients also suffer from one or more serious health conditions such as diabetes, hypertension or heart failure that are either aggravated or caused by OSA. Treating OSA reduces medical expenses, improves patient quality of life and lowers associated health risks.

About NovaSom, Inc.

NovaSom, Inc. is the market leader in Obstructive Sleep Apnea (OSA) home testing, with the AccuSom® Home Sleep Test, the first and only FDA-cleared wireless HST. The NovaSom home sleep testing technology and MediTrack® portal have been shown to provide in-home, clinically equivalent diagnosis of OSA at a significantly reduced cost as compared to in-facility testing for uncomplicated, adult OSA. NovaSom’s home sleep tests are currently covered for more than 165 million U.S. lives, through partnerships with major health insurers.

NovaSom also offers comprehensive service programs that are utilized by payers, employers, primary care and sleep specialist physicians nationwide, that enable significant cost savings for OSA management. In an effort to combat the growing OSA epidemic, NovaSom also partners with sleep centers, enabling sleep specialists to offer clinically appropriate patients an alternative, convenient testing option, expanding access to diagnosis and treatment.

NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider and is classified by CMS as an Independent Diagnostic Testing Facility. For more information, visit www.NovaSom.com.

Media:
NovaSom, Inc.
Isabel Portieles, 410-590-0443
iportieles@NovaSom.com

Source: NovaSom, Inc.

SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/bIVl

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?